Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
University of Southern California
Modality
vaccine
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00334776CT.gov Vaccine Therapy in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00031733CT.gov Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma | — | Completed | — | — | — |
NCT00036816CT.gov Vaccine Therapy in Treating Patients With Melanoma of the Eye | — | Terminated | — | — | — |
NCT00025181CT.gov Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery | — | Completed | — | — | — |
NCT00020475CT.gov Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye | — | Completed | — | — | — |
NCT00005841CT.gov Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Uveal Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mart-1 Antigen (this asset) | University of Southern California | P3 | BB · 64 |
| Ifa | Craig L Slingluff, Jr | P2 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2/3 | BB |
| Sargramostim | Thomas Jefferson University | P3 | BB |
| Darovasertib | IDEAYA Biosciences | P3 | BB |
| Gm-Csf | Ahmad Tarhini | P2 | BB |
| Pembrolizumab | BioInvent International AB | P2/3 | BB |
| Thalidomide | Memorial Sloan Kettering Cancer Center | P2 | BB |
+42 more in the Uveal Melanoma cohort
Other indications for Mart-1 Antigen
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cutaneous Melanoma | — | P2 | BB · 70 |
| Melanoma | — | P2 | BB · 64 |
| Metastatic Melanoma | — | P2 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Mart-1 Antigen in Uveal Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mart-1-antigen-uveal-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →